- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00600795
Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The goal of this research is to investigate a potential CSF biomarker of NPH as a new tool for both the diagnosis of NPH and prognosis of VPS placement. Transforming growth factor-b1 (TGF-b1) is a signaling molecule involved in three fundamental activities; suppression of cell proliferation, immunosuppression, and deposition of extracellular matrix through promotion of synthesis and inhibition of degradation.8 Previously, TGF-b1 had been implicated in the development of communicating hydrocephalus secondary to pre-term infant intraventricular hemorrhage9 and adult aneurysmal sub-arachnoid hemorrhage.10, 11 Recently, an investigation demonstrated elevated levels of TGF-b1 in patients with shunt-responsive NPH compared to non-NPH patients.12
The specific aims of this research proposal are to:
- Correlate CSF levels of TGF-b1 with the clinical response of patients diagnosed with NPH to VPS placement.
- Correlate CSF levels of TGF-b1 with optimal VPS pressure settings.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of Normal Pressure Hydrocephalus
Exclusion Criteria:
- Patients not diagnosed with Normal Pressure Hydrocephalus
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
A
Patients diagnosed with Normal Pressure Hydrocephalus
|
CSF collection at time of VPS insertion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
TGF beta-1 levels
Time Frame: Time of Surgery
|
Time of Surgery
|
|
Mini-mental status exam
Time Frame: Pre-operative, 3 and 12 months post-operatively
|
Pre-operative, 3 and 12 months post-operatively
|
|
Modified barthel index
Time Frame: Pre-operative, 3 and 12 months post-operatively
|
Pre-operative, 3 and 12 months post-operatively
|
|
Tinetti mobility assessment
Time Frame: Pre-operative, 3 and 12 months post-operatively
|
Pre-operative, 3 and 12 months post-operatively
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Programmable shunt setting
Time Frame: Pre-operative, 3 and 12 months post-operatively
|
Pre-operative, 3 and 12 months post-operatively
|
Collaborators and Investigators
Investigators
- Principal Investigator: Noel Tulipan, M.D., Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 070875
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Pressure Hydrocephalus
-
Göteborg UniversityDepartment of Neurological Surgery, Sahlgrenska University Hospital; Hydrocephalus... and other collaboratorsNot yet recruitingNormal Pressure Hydrocephalus | Normal Pressure Hydrocephalus Patients
-
Mayo ClinicTerminatedNormal Pressure Hydrocephalus PatientsUnited States
-
Umeå UniversityCompleted
-
Dokuz Eylul UniversityRecruitingNPH (Normal Pressure Hydrocephalus)Turkey
-
Second Affiliated Hospital, School of Medicine,...Westlake UniversityRecruitingIdiopathic Normal Pressure HydrocephalusChina
-
University of ZurichCompletedIdiopathic Normal Pressure HydrocephalusSwitzerland
-
University Hospital Hradec KraloveCompletedHydrocephalus | Normal Pressure Hydrocephalus | Normal Pressure Hydrocephalus PatientsCzech Republic
-
Translational Research Center for Medical Innovation...Johnson & Johnson; Codman & Shurtleff; Eisai Limited; Nihon Medi-Physics Co., Ltd. and other collaboratorsCompletedIdiopathic Normal Pressure HydrocephalusJapan
-
Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingIdiopathic Normal Pressure Hydrocephalus (INPH)United States, Canada, Sweden
-
University of ZurichETH ZurichCompletedIdiopathic Normal Pressure Hydrocephalus (INPH)Switzerland
Clinical Trials on CSF collection
-
Hospices Civils de LyonRecruiting
-
GlaxoSmithKlineCompletedHaemophilus Influenzae | Neisseria Meningitidis | Streptococcus PneumoniaePhilippines, Vietnam
-
St. Joseph's Hospital and Medical Center, PhoenixTranslational Genomics Research InstituteTerminatedIntraventricular Hemorrhage | Spina BifidaUnited States
-
Hospices Civils de LyonRecruitingParkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid PolyarthritisFrance
-
Jules Bordet InstituteBristol-Myers Squibb; Fondation Cancer, Luxembourg; Fondation Cancer, Belgique; Les AmisRecruitingCNS MetastasesBelgium, France, Luxembourg
-
National Institute of Allergy and Infectious Diseases...Novartis Pharmaceuticals; Autoimmunity Centers of ExcellenceCompletedSecondary Progressive Multiple SclerosisUnited States
-
Centre Hospitalier Régional d'OrléansImmunologie et Neurogénétique Expérimentales et Moléculaires (INEM)WithdrawnInflammation | Guillain-Barre Syndrome | Sclerosis, MultipleFrance
-
Leiden University Medical CenterUniversity of Ulm; Brighton & Sussex Medical SchoolRecruiting
-
Hospices Civils de LyonRecruitingParaneoplastic Neurological Syndromes or Autoimmune EncephalitisFrance